• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Keen Vision Acquisition Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits

    7/24/25 4:00:48 PM ET
    $KVAC
    Get the next $KVAC alert in real time by email
    false --12-31 0001889983 00-0000000 0001889983 2025-07-22 2025-07-22 0001889983 KVACW:UnitsEachConsistingOfOneOrdinaryShareAndOneRedeemableWarrantToAcquireOneOrdinaryShareMember 2025-07-22 2025-07-22 0001889983 KVACW:OrdinaryShares0.0001ParValueMember 2025-07-22 2025-07-22 0001889983 KVACW:WarrantsEachExercisableForOneOrdinaryShareAtExercisePriceOf11.50Member 2025-07-22 2025-07-22 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    United States

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    Form 8-K

     

    Current Report

    Pursuant to Section 13 or 15(d) of the

    Securities Exchange Act of 1934

     

    July 22, 2025

    Date of Report (Date of earliest event reported)

     

    KEEN VISION ACQUISITION CORPORATION

    (Exact Name of Registrant as Specified in its Charter)

     

    British Virgin Islands   001-41753   n/a
    (State or other jurisdiction
    of incorporation)
      (Commission File Number)   (I.R.S. Employer
    Identification No.)

     

    37 Greenbriar Drive
    Summit, New Jersey
      07901
    (Address of Principal Executive Offices)   (Zip Code)

     

    Registrant’s telephone number, including area code: (203) 609-1394

     

    N/A

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act

     

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act

     

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act

     

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act

     

    Securities registered pursuant to Section 12(b) of the Act: None.

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Units, each consisting of one ordinary share and one redeemable warrant to acquire one ordinary share   KVACU   The Nasdaq Stock Market LLC
    Ordinary Shares, $0.0001 par value   KVAC   The Nasdaq Stock Market LLC
    Warrants, each exercisable for one ordinary share at an exercise price of $11.50   KVACW   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 1.01. Entry Into a Material Definitive Agreement

     

    Amendment to the Investment Management Trust Agreement

     

    As approved by its shareholders at the extraordinary shareholders meeting held on July 22, 2025 (the “Meeting”), Keen Vision Acquisition Corporation (“KVAC”) entered into an amendment to the Investment Management Trust Agreement, with Continental Stock Transfer & Trust Company (the “Trust Amendment”) dated as of July 23, 2025. Pursuant to the Trust Amendment, KVAC has the right to extend the time for KVAC to complete its business combination (the “Business Combination Period”) under the Trust Agreement for a period of six months from July 27, 2025 to January 27, 2026, by depositing into the Trust Account $0.03 for each remaining public share (the “Extension Payment”) for each one-month extension. The foregoing description of the Trust Amendment is qualified in its entirety by reference to the full text of the Trust Amendment, a copy of which is filed with this Current Report on Form 8-K as Exhibit 10.1, and is incorporated herein by reference.

     

    Promissory Note

     

    On July 23, 2025, the Company issued an unsecured promissory note in the aggregate principal amount of $144,670.38 (the “Note”) to KVC Sponsor LLC, the Company’s initial public offering sponsor (“Sponsor”) in exchange for Sponsor depositing such amount into the Company’s trust account in order to extend the amount of time it has available to complete a business combination. The Note does not bear interest and matures upon the closing of a business combination by the Company. In addition, the Note may be converted by the holder into units of the Company identical to the units issued in the Company’s initial public offering at a price of $10.00 per unit.

     

    Item 5.03. Amendments to Articles of Incorporation or Bylaws.

     

    As approved by its shareholders at the Meeting, KVAC filed its third amended and restated memorandum and articles of association (the “M&AA”) with the British Virgin Islands Registry on July 23, 2025.

     

    The foregoing description of KVAC’s M&AA is qualified in its entirety by reference to the full text of KVAC’s M&AA, a copy of which is filed with this Current Report on Form 8-K as Exhibit 3.1, and is incorporated herein by reference.

     

    Item 5.07. Submission of Matters to a Vote of Security Holders.

     

    On July 22, 2025, KVAC held the Meeting. On June 27, 2025, the record date for the Meeting, there were 10,820,727 ordinary shares of KVAC entitled to be voted at the Meeting, of which 8,213,555, or approximately 75.91% of the total outstanding ordinary shares of KVAC, were represented in person or by proxy; therefore, a quorum was present.

     

    1

     

     

    1. Trust Amendment

     

    Shareholders approved the proposal to amend KVAC’s Investment Management Trust Agreement by and between KVAC and Continental Stock Transfer & Trust Company, dated as of July 24, 2023, giving KVAC the right to extend the Business Combination Period from July 27, 2025 to January 27, 2026 by depositing $0.03 for each public share for each one month extended. Adoption of the Trust Amendment required approval by the affirmative vote of at least 50% of the outstanding shares. The voting results were as follows:

     

    FOR   AGAINST   ABSTAIN
    8,213,544   0   11

     

    2. Charter Amendment

     

    Shareholders approved the proposal (the “Charter Amendment Proposal”) to amend KVAC’s M&AA, giving KVAC the right to extend the Business Combination Period from July 27, 2025 to January 27, 2026 by depositing $0.03 for each public share for each one month extended. The approval of the Charter Amendment Proposal requires a resolution of members under the M&AA, being the affirmative vote of a majority of the Company’s ordinary shares issued and outstanding and entitled to vote and which are present (in person or by proxy) at the Meeting and which voted on the matter is required. The voting results were as follows:

     

    FOR   AGAINST   ABSTAIN
    8,213,544   0   11

     

    Item 8.01. Other Events.

     

    In connection with the shareholders’ vote at the Annual Meeting, 1,582,306 shares were tendered for redemption.

     

    Item 9.01. Financial Statements and Exhibits

     

    Exhibit No.   Description
    3.1   Third Amended and Restated Memorandum and Articles of Association of KVAC
    10.1   Amendment to the Investment Management Trust Agreement between KVAC and Continental Stock Transfer & Trust Company dated July 23, 2025
    10.2   Promissory Note dated July 23, 2025
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

    2

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Dated: July 24, 2025 Keen Vision Acquisition Corporation
         
      By: /s/ WONG, Kenneth Ka Chun
      Name:  WONG, Kenneth Ka Chun
      Title: Chief Executive Officer

     

    3

     

    Get the next $KVAC alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KVAC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $KVAC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Medera's Novoheart Enters New Collaboration to Develop Human Mini-Heart Models Aimed at Transforming Treatment for Hypoplastic Left Heart Syndrome

    First-ever mini-Heart models will be created from hypoplastic left heart syndrome (HLHS) patient stem cells, enabling personalized insights into their causes and treatmentsPartnership aims to improve survival and quality of life for pediatric HLHS patients by developing new tools that can identify which children will potentially benefit most from surgery, transplantation, or novel therapiesLeveraging Novoheart's proprietary mini-Heart Platform, this partnership aligns with emerging FDA guidelines supporting human-relevant, animal-free drug development BOSTON and SAN DIEGO and ROCHESTER, Minn., June 24, 2025 (GLOBE NEWSWIRE) -- Medera Inc. ("Medera"), a clinical-stage biopharmaceutical com

    6/24/25 8:00:00 AM ET
    $KVAC

    Medera Presented Updated Results from First-In-Human Gene Therapy Trial for Heart Failure with Preserved Ejection Fraction at 2025 HFpEF Summit

    BOSTON, April 01, 2025 (GLOBE NEWSWIRE) -- Medera Inc. ("Medera"), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by developing a range of next-generation therapeutics, today announced that updated results from its ongoing MUSIC-HFpEF Phase 1/2a clinical trial investigating SRD-002, a one-time gene therapy treatment delivered through a proprietary minimally invasive intracoronary infusion methodology, were presented at the 2025 HFpEF Summit held March 19-21, 2025, in Beverly Hills, CA. Heart failure is a global pandemic with an estimated 64.3 million cases worldwide, costing over US$100B per year. Heart failure with preserved ejection fraction (HFp

    4/1/25 8:00:00 AM ET
    $KVAC

    Medera Receives DSMB Clearance to Initiate Phase 2 Portion of MUSIC-HFrEF Phase 1b/2 Trial for SRD-001 Gene Therapy in Heart Failure with Reduced Ejection Fraction

    BOSTON, March 20, 2025 (GLOBE NEWSWIRE) -- Medera Inc. ("Medera"), a clinical-stage biopharmaceutical company focused on cardiovascular diseases with high unmet need by developing a range of next-generation therapeutics, today announced that the independent Data and Safety Monitoring Board (DSMB) has completed its planned review of the MUSIC-HFrEF Phase 1b/2 clinical trial data, recommending the completion of the Phase 1b portion and clearance to initiate the Phase 2 portion of the trial evaluating the gene therapy candidate SRD-001 in patients with heart failure with reduced ejection fraction (HFrEF). HFrEF is a prevalent form of heart disease that accounts for half of an estimated 64.3

    3/20/25 8:00:00 AM ET
    $KVAC

    $KVAC
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Keen Vision Acquisition Corporation

    SCHEDULE 13G/A - Keen Vision Acquisition Corp. (0001889983) (Subject)

    8/13/25 6:12:36 AM ET
    $KVAC

    SEC Form 10-Q filed by Keen Vision Acquisition Corporation

    10-Q - Keen Vision Acquisition Corp. (0001889983) (Filer)

    8/11/25 4:00:46 PM ET
    $KVAC

    Amendment: SEC Form SCHEDULE 13G/A filed by Keen Vision Acquisition Corporation

    SCHEDULE 13G/A - Keen Vision Acquisition Corp. (0001889983) (Subject)

    8/8/25 5:36:19 PM ET
    $KVAC

    $KVAC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Keen Vision Acquisition Corporation

    SC 13G - Keen Vision Acquisition Corp. (0001889983) (Subject)

    11/14/24 9:07:56 PM ET
    $KVAC

    SEC Form SC 13G filed by Keen Vision Acquisition Corporation

    SC 13G - Keen Vision Acquisition Corp. (0001889983) (Subject)

    11/14/24 6:03:06 PM ET
    $KVAC

    Amendment: SEC Form SC 13G/A filed by Keen Vision Acquisition Corporation

    SC 13G/A - Keen Vision Acquisition Corp. (0001889983) (Subject)

    11/12/24 4:07:50 PM ET
    $KVAC